WO2019078634A3 - Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein - Google Patents
Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein Download PDFInfo
- Publication number
- WO2019078634A3 WO2019078634A3 PCT/KR2018/012322 KR2018012322W WO2019078634A3 WO 2019078634 A3 WO2019078634 A3 WO 2019078634A3 KR 2018012322 W KR2018012322 W KR 2018012322W WO 2019078634 A3 WO2019078634 A3 WO 2019078634A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin resistance
- fatty liver
- prevention
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Abstract
The present invention relates to a pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising a PTP4A1 protein or a polynucleotide coding for the PTP4A1 protein. Overexpression of PTP4A1 protein results in the effect of alleviating insulin resistance and suppressing fatty liver production so that the PTP4A1 protein of the present invention can be effectively used as a therapeutic agent in the metabolic syndrome field.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170135408A KR102496229B1 (en) | 2017-10-18 | 2017-10-18 | Pharmaceutical Composition Comprising PTP4A1 Protein for Prevention or Treatment Insulin Resistance or Non-alcoholic Fatty liver |
KR10-2017-0135408 | 2017-10-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019078634A2 WO2019078634A2 (en) | 2019-04-25 |
WO2019078634A3 true WO2019078634A3 (en) | 2019-06-20 |
Family
ID=66174150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/012322 WO2019078634A2 (en) | 2017-10-18 | 2018-10-18 | Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102496229B1 (en) |
WO (1) | WO2019078634A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102216646B1 (en) * | 2018-11-23 | 2021-02-17 | 차의과학대학교 산학협력단 | A composition comprising mesenchymal stem cell for inhibiting adipogenesis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258692A1 (en) * | 2002-10-31 | 2006-11-16 | Mark Pines | Quinazolinone compositions for regulation of gene expression related to pathological processes |
WO2010040571A2 (en) * | 2008-10-10 | 2010-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
KR20160000041A (en) * | 2014-06-23 | 2016-01-04 | 주식회사 바이오포트코리아 | Composition comprising ginseng berry extract for preventing or treating diabetic and diabetic complication |
KR20160084528A (en) * | 2015-01-05 | 2016-07-14 | 서울대학교산학협력단 | A protein biomarker for early diagnosis of type 2 diabetes mellitus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017030410A1 (en) | 2015-08-19 | 2017-02-23 | 한국생명공학연구원 | Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glycosides isolated therefrom as active ingredients |
-
2017
- 2017-10-18 KR KR1020170135408A patent/KR102496229B1/en active IP Right Grant
-
2018
- 2018-10-18 WO PCT/KR2018/012322 patent/WO2019078634A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258692A1 (en) * | 2002-10-31 | 2006-11-16 | Mark Pines | Quinazolinone compositions for regulation of gene expression related to pathological processes |
WO2010040571A2 (en) * | 2008-10-10 | 2010-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
KR20160000041A (en) * | 2014-06-23 | 2016-01-04 | 주식회사 바이오포트코리아 | Composition comprising ginseng berry extract for preventing or treating diabetic and diabetic complication |
KR20160084528A (en) * | 2015-01-05 | 2016-07-14 | 서울대학교산학협력단 | A protein biomarker for early diagnosis of type 2 diabetes mellitus |
Non-Patent Citations (1)
Title |
---|
HWANG, BYUNG TAE: "The Multifunctional Roles of PTP4A1 in Angiogenesis and Insulin Resistance", UNIV. OF SCIENCE AND TECHNOLOGY, LIFE SCIENCE BIOMOLECULE SCIENCE, August 2017 (2017-08-01), pages 47, 50, 51, 67 * |
Also Published As
Publication number | Publication date |
---|---|
KR20190043397A (en) | 2019-04-26 |
KR102496229B1 (en) | 2023-02-06 |
WO2019078634A2 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
MX2018007704A (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant. | |
EP3173092A3 (en) | Rna containing composition for treatment of tumor diseases | |
HK1254897A1 (en) | Composition of lactic bacteria for use in the treatment of infections due to propionibacterium acnes and in particular for acne | |
WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
EP3111931A4 (en) | Pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients | |
WO2014190163A3 (en) | Combination therapy for mds | |
EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
MX2023000796A (en) | Pharmaceutical composition, methods for treating and uses thereof. | |
WO2016142708A3 (en) | Pharmaceutical composition | |
WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
IL259183B (en) | Food supplement and composition for treating the metabolic syndrome | |
WO2018093238A3 (en) | Composition comprising as active ingredient strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity | |
WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
EP3661600A4 (en) | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | |
WO2019078634A3 (en) | Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein | |
PH12017501120A1 (en) | Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes | |
WO2016178510A3 (en) | Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3 | |
WO2015140798A3 (en) | Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof | |
EP3265108A4 (en) | Peptides and compositions comprising same and uses thereof in the treatment of diseases | |
EP3338792A4 (en) | Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients | |
WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
EP3815690A4 (en) | Application of composition of mannuronic diacid in treating diabetes | |
EP3366292A4 (en) | Composition for preventing or treating obesity containing alpha-lipoic acid and n-acetylcysteine as active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18868993 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18868993 Country of ref document: EP Kind code of ref document: A2 |